Axogen Inc (AXGN)

Currency in USD
14.90
+0.14(+0.95%)
Closed·
15.00+0.10(+0.67%)
·
AXGN Scorecard
Full Analysis
Net income is expected to grow this year
AXGN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
14.1014.95
52 wk Range
9.2221.00
Key Statistics
Prev. Close
14.76
Open
14.53
Day's Range
14.1-14.95
52 wk Range
9.22-21
Volume
1.35M
Average Volume (3m)
1.1M
1-Year Change
38.6%
Book Value / Share
2.47
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AXGN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
24.71
Upside
+65.87%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in overbought territory

Axogen Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Axogen Inc Company Profile

Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. Axogen, Inc. is headquartered in Alachua, Florida.

Axogen Inc SWOT Analysis


Nerve Repair Pionee
AxoGen leads in peripheral nerve injury solutions, with a growing $5.6 billion market and innovative products driving expansion into new segments like prostate care
Financial Resilience
Q1 2025 revenue of $48.6M, up 17.4% YoY. Full-year guidance of $215.4M-$219.1M reaffirmed, projecting 15-17% growth. Analysts forecast $248M by 2026
Regulatory Catalyst
Anticipated BLA approval for Avance Nerve Graft in September 2025 could boost adoption, secure market exclusivity, and establish it as the standard of care
Strategic Vision
New CEO Michael Dale's seven-point plan aims for cash flow positivity by 2025-2028, with $70M+ annual operational cash flow by 2028, self-funding future growth
Read full SWOT analysis

Axogen Inc Earnings Call Summary for Q1/2025

  • AxoGen reported Q1 2025 adjusted net loss of $0.02/share, missing $0.02 EPS forecast; revenue grew 17.4% YoY to $48.6M, slightly below expectations
  • Stock tumbled 14.28% premarket on earnings miss; company maintains 15-17% full-year revenue growth guidance and 73-75% gross margin target
  • Expanding sales force and targeting high-potential accounts; expects BLA approval for AVANCE nerve graft in September
  • CEO emphasizes focus on high-potential providers and positioning to address nerve injury challenges; aims to be cash flow positive
  • Analysts maintain strong buy consensus with price targets $24-$30; InvestingPro data suggests current valuation is fairly valued
Last Updated: 08/05/2025, 14:22
Read Full Transcript

Compare AXGN to Peers and Sector

Metrics to compare
AXGN
Peers
Sector
Relationship
P/E Ratio
−147.0x−3.6x−0.5x
PEG Ratio
−1.98−0.110.00
Price/Book
6.1x3.3x2.6x
Price / LTM Sales
3.4x2.7x3.3x
Upside (Analyst Target)
69.4%70.9%40.6%
Fair Value Upside
Unlock7.1%5.3%Unlock

Analyst Ratings

7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 24.71
(+65.87% Upside)

Earnings

Latest Release
Aug 05, 2025
EPS / Forecast
0.12 / 0.06
Revenue / Forecast
56.66M / 52.66M
EPS Revisions
Last 90 days

AXGN Income Statement

People Also Watch

44.92
STNG
-0.20%
17.810
ZETA
-3.42%
18.78
ARWR
-6.05%
8.900
ZVRA
-5.62%
5.35
REPL
+5.11%

FAQ

What Stock Exchange Does Axogen Inc Trade On?

Axogen Inc is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Axogen Inc?

The stock symbol for Axogen Inc is "AXGN."

What Is the Axogen Inc Market Cap?

As of today, Axogen Inc market cap is 685.59M.

What Is Axogen Inc's Earnings Per Share (TTM)?

The Axogen Inc EPS (TTM) is -0.10.

When Is the Next Axogen Inc Earnings Date?

Axogen Inc will release its next earnings report on 10 Nov 2025.

From a Technical Analysis Perspective, Is AXGN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Axogen Inc Stock Split?

Axogen Inc has split 0 times.

How Many Employees Does Axogen Inc Have?

Axogen Inc has 452 employees.

What is the current trading status of Axogen Inc (AXGN)?

As of 15 Aug 2025, Axogen Inc (AXGN) is trading at a price of 14.90, with a previous close of 14.76. The stock has fluctuated within a day range of 14.10 to 14.95, while its 52-week range spans from 9.22 to 21.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.